NHWD 870

Drug Profile

NHWD 870

Alternative Names: NHWD-870

Latest Information Update: 27 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ningbo Wenda Pharma
  • Class Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; Mitogen-activated protein kinase inhibitors; Platelet-derived growth factor beta receptor modulators; Platelet-derived growth factor inhibitors; Proto oncogene protein c-myc inhibitors; Proto-oncogene protein inhibitors; STAT1 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Cancer in China
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top